Emerging strategies for the treatment of advanced small cell lung cancer
- PMID: 27867600
- PMCID: PMC5107470
- DOI: 10.21037/jtd.2016.10.46
Emerging strategies for the treatment of advanced small cell lung cancer
Conflict of interest statement
TAY has received research support from AstraZeneca and Merck, and has served on Advisory Boards and received travel support from Pfizer and Bristol Myers Squibb. J S Lim is supported by the National Medical Research Council (NMRC) Research Training Fellowship, Singapore.
Figures
Comment on
-
A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.Clin Cancer Res. 2016 Oct 15;22(20):5120-5129. doi: 10.1158/1078-0432.CCR-15-3068. Epub 2016 Jun 7. Clin Cancer Res. 2016. PMID: 27267850 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources